RxDoctor Payments Data

David Zich, MD

Internal Medicine · Chicago, ILNPI 1013022565

Payments from drug & device makers

$8,167in general payments, 2019–2025

Across 418 payments — averaging $19.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$2K
  • Novo Nordisk$1K
  • AstraZeneca$545
  • Boehringer Ingelheim$423
  • Eisai Inc.$373
  • Takeda Pharmaceuticals U.S.A., Inc.$365
  • plus $3K from 33 others

What the payments were for

  • Food & beverage$8,06799%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,167 in reported general payments places this provider in the 90th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$74,790
Medicare patients
205
Services billed
967

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban71$108,423
JardianceEmpagliflozin35$58,894
WegovySemaglutide15$21,662
FarxigaDapagliflozin Propanediol12$17,683
JanuviaSitagliptin Phosphate12$17,673
OzempicSemaglutide15$17,601
RybelsusSemaglutide14$17,498
XareltoRivaroxaban14$13,483
SymbicortBudesonide/Formoterol Fumarate14$4,443
AliskirenAliskiren Hemifumarate17$4,005
SynthroidLevothyroxine Sodium31$3,768
Atorvastatin Calcium288$3,661
Olmesartan Medoxomil150$3,373
BenicarOlmesartan Medoxomil11$3,308
Estradiol22$2,994

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,698$108,42371 claims
Boehringer IngelheimJardiance$423$58,89435 claims
Novo NordiskWegovy, Ozempic, Rybelsus$1,356$56,76144 claims
AstraZenecaFarxiga, Symbicort$545$22,12726 claims
MerckJanuvia$223$17,67312 claims
Johnson & JohnsonXarelto$102$13,48314 claims
AbbVieSynthroid$103$3,76831 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$16$1,784102 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →